The EMA cleared RYEQO in July 2021 for the treatment of uterine fibroids.
RYEQO contains 40 mg relugolix, which reduces the amount of estrogen and other hormones produced by the ovaries, 1 mg estradiol, which may reduce the risk of bone loss, and 0.5 mg norethisterone acetate, a progestin that is necessary when women with a uterus take estrogen.
Richter's RYEQO sales came to EUR 1.8 million in H1 2022, according to the company's latest earnings report.
Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
